Clinical Trial Update: Proof-of-concept Trial of IVA337 in Diffuse Cutaneous Systemic Sclerosis [Phase 2]

View source ↗

Summary

Phase 2 proof-of-concept trial of IVA337 in diffuse cutaneous systemic sclerosis (scleroderma) completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Cutaneous Systemic Sclerosis
• Scleroderma Diffuse

Drugs mentioned

• IVA337 (unlisted)

Snippet

Sponsor: Inventiva Pharma | Conditions: Scleroderma, Diffuse, Diffuse Cutaneous Systemic Sclerosis | Phase 2 | Status: COMPLETED